SCHEMBL4495244

SCHEMBL4495244

CC(C)(C)OC(=O)NC1CCN(c2ncc(C(F)(F)F)cc2Cl)CC1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 9/20 0.58
▸ LMNA P02545 3/20 0.58
▸ KMT2A Q03164 5/20 0.56
▸ MAPT P10636 4/20 0.56
▸ MEN1 O00255 4/20 0.56
▸ CYP2C9 P11712 3/20 0.56
▸ CYP2C19 P33261 3/20 0.56
▸ KDM4E B2RXH2 3/20 0.56
▸ GAA P10253 1/20 0.56
▸ ALDH1A1 P00352 6/20 0.54
▸ POLB P06746 3/20 0.54
▸ HPGD P15428 2/20 0.54
▸ HTT P42858 1/20 0.52
▸ NPC1 O15118 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.50
▸ RECQL P46063 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30497704 1.00 SMN1; SMN2 (0.58) SMN1; SMN2LMNAKMT2AMAPTMEN1
SCHEMBL1350088 0.90 MAPT (0.56) SMN1; SMN2LMNAKMT2AMAPTMEN1
SCHEMBL28605629 0.88 JAK3 (0.54) SMN1; SMN2LMNAKMT2AMAPTMEN1
SCHEMBL28605626 0.88 JAK3 (0.54) SMN1; SMN2LMNAKMT2AMAPTMEN1
SCHEMBL31124452 0.88 JAK3 (0.54) SMN1; SMN2LMNAKMT2AMAPTMEN1
SCHEMBL31124509 0.88 JAK3 (0.54) SMN1; SMN2LMNAKMT2AMAPTMEN1
SCHEMBL28614144 0.88 JAK3 (0.54) SMN1; SMN2LMNAKMT2AMAPTMEN1
SCHEMBL3134267 0.87 DRD2 (0.60) SMN1; SMN2LMNAKMT2AMAPTMEN1
SCHEMBL3134259 0.87 DRD2 (0.60) SMN1; SMN2LMNAKMT2AMAPTMEN1
SCHEMBL31124457 0.85 SMN1; SMN2 (0.51) SMN1; SMN2LMNAKMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3793552-B1 ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME SCRIPPS RESEARCH INST (US) 2023-07-12 — — EP disclosed
US-20210221790-A1 ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME H. LUNDBECK A/S (DK) 2021-07-22 — — US disclosed
US-7528151-B2 Heterocyclic urea derivatives for the treatment of pain GLAXO GROUP LIMITED (GB) 2009-05-05 — — US disclosed
US-20070117820-A1 Heterocyclic urea derivatives for the treatment of pain KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-05-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117820-A1 Heterocyclic urea derivatives for the treatment of pain U2SURP, UMPS, SFPQ SMN1; SMN2 855/4885LMNA 2076/4885KMT2A 2859/4885
US-20210221790-A1 ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME ABHD12, SAMHD1, ABHD11 SMN1; SMN2 3224/4885LMNA 4313/4885KMT2A 1806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback